Revised SPC: Blincyto (blinatumomab)

SPC now warns that lineage switch from ALL to AML has been rarely reported in relapsed patients receiving BLINCYTO, including those with no immunophenotypic and/or cytogenetic abnormalities at initial diagnosis. All relapsed patients should be monitored for presence of AML.

Source:

electronic Medicines compendium